| Literature DB >> 33584677 |
Inga Koneczny1, Vuslat Yilmaz2, Konstantinos Lazaridis3, John Tzartos4,5, Tobias L Lenz6, Socrates Tzartos4,7, Erdem Tüzün2, Frank Leypoldt8.
Abstract
IgG4 autoimmune diseases (IgG4-AID) are an emerging group of autoimmune diseases that are caused by pathogenic autoantibodies of the IgG4 subclass. It has only recently been appreciated, that members of this group share relevant immunobiological and therapeutic aspects even though different antigens, tissues and organs are affected: glomerulonephritis (kidney), pemphigus vulgaris (skin), thrombotic thrombocytopenic purpura (hematologic system) muscle-specific kinase (MuSK) in myasthenia gravis (peripheral nervous system) and autoimmune encephalitis (central nervous system) to give some examples. In all these diseases, patients' IgG4 subclass autoantibodies block protein-protein interactions instead of causing complement mediated tissue injury, patients respond favorably to rituximab and share a genetic predisposition: at least five HLA class II genes have been reported in individual studies to be associated with several different IgG4-AID. This suggests a role for the HLA class II region and specifically the DRβ1 chain for aberrant priming of autoreactive T-cells toward a chronic immune response skewed toward the production of IgG4 subclass autoantibodies. The aim of this review is to provide an update on findings arguing for a common pathogenic mechanism in IgG4-AID in general and to provide hypotheses about the role of distinct HLA haplotypes, T-cells and cytokines in IgG4-AID.Entities:
Keywords: HLA class II; HLA-DQB1; HLA-DRB1; IgG4 autoimmune disease; MHC; autoimmunity; etiology
Mesh:
Substances:
Year: 2021 PMID: 33584677 PMCID: PMC7878376 DOI: 10.3389/fimmu.2020.605214
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561